

Prevalence and immunization coverage of asplenic patients at a community hospital in Omaha, Nebraska

Dain Finke, M.D., M.P.H, Linda Ohri, Pharm.D., M.P.H, Rudolf Kotula, M.D., Immunization Task Force – Metro Omaha, Methodist Physicians Clinic

Background

- The spleen plays an important role in immune response to infections caused by encapsulated bacteria: Streptococcus pneumoniae (50-90% of cases), Neisseria meningitidis, and Haemophilus influenzae type B
- Patients with reduced or absent splenic function are at high risk for infections by encapsulated bacteria which can cause rapidly progressive meningitis, pneumonia and/or sepsis, referred to as Overwhelming Post-Splenectomy Infections (OPSI)
 - Before widespread immunization, the lifetime risk of developing OPSI was 3.2%, with a mortality rate of nearly 50% among patients that develop OPSI
 - Immunizations reduce the risk of developing OPSI
- Causes of asplenia include:
 - Surgical Splenectomy the surgical removal of the spleen, most commonly secondary to trauma that causes splenic rupture and hemorrhage
 - Diseases causing damage to the spleen like: Sickle Cell Anemia, Hereditary Spherocytosis, Immune Thrombocytopenia purpura, Thalassemia
- Immunizations recommended for asplenic patients include:
 - Pneumococcal (PCV13 and PPSV23)
 - Hib Conjugate
 - Meningococcal (both ACWY and MenB vaccines)
 - Influenza

Methods

- A retrospective cohort of asplenic patients in the Nebraska Methodist Health System
- Collaboration between Methodist Physicians Clinic (MPC) and the Immunization Task Force (ITF) – Metro Omaha
- Patients included in the study met all the following conditions:
 - 1. Had a patient record in the Methodist Health system
 - 2. Had a clinical visit or hospital admission in the past five years
 - 3. Had a billing code related to asplenia
- MPC coding and billing staff pulled de-identified information regarding patient's current immunization status

Results

	Total (N=519)	Congenital (n=33)	Acquired (n=486)	Acquired (n=486)				
				Surgical Splenectomy (n=98)	Unknown (n=388)			
Age in Years								
Mean (Range)	60.2 (1-99)	57 (1-79)	60 (17-99)	61 (22-99)	60 (17-96)			
Under 65	295 (56.8%)	26 (78.8%)	269 (55.4%)	64 (65.3%)	205 (52.8%)			
65 and Above	224 (43.2%)	7 (21.2%)	217 (44.7%)	34 (34.7%)	183 (47.2%)			
Immunization								
Meningococcal ACWY	45 (8.7%)	1 (3.0%)	44 (9.1%)	9 (9.2%)	35 (9.0%)			
Pneumococcal	430 (82.9%)	29 (87.9%)	401 (85.5%)	86 (87.8%)	315 (81.2%)			
Hib	121 (23.3%)	8 (24.2%)	113 (23.6%)	37 (37.8%)	76 (19.6%)			
Influenza in the past vear	222 (42.8%)	16 (48.5%)	206 (42.4%)	38 (38.8%)	168 (43.3%)			

т (1	Total (N=519)	Congenital (n=33)	Acquired (n=486)	Acquired (n=486)				
				Surgical Splenectomy (n=98)	Unknown (n=388)			
Immunization Coverage								
At least one dose of all recommended vaccines	8 (1.5%)	0 (0%)	8 (1.6%)	0 (0%)	8 (2.1%)			
Has not received a dose of any recommended vaccine	44 (8.5%)	3 (9.1%)	41 (8.4%)	9 (9.2%)	32 (8.3%)			

* Notes: Only one pneumococcal vaccination was listed; Men B vaccination was not listed

Discussion

- Results reflect a limited but crucial first step in characterizing this Health System's asplenia population
- Data suggests there is room to improve immunization coverage for all of the recommended vaccines
 - Only eight (1.5%) patients had documentation of at least one • dose of all recommended vaccines
- Pneumococcal coverage was highest among the recommended vaccines. 82.9% of patients had received at least one dose of one pneumococcal vaccine (either PCV13 *or* PPSV23)
 - Both PCV13 and PPSV23 are recommended for asplenic patients; data on coverage of both vaccines was unavailable



Limitations

It is important to consider the project's constraints when interpreting the results

- 1. Data did not reflect number of doses given or completion of a series
- 2. Only PPSV23 or PCV13 administration was listed
- 3. Data did not include MenB coverage
- 4. The underlying cause of acquired asplenia was not provided
- 5. There was no information on occurrence of OPSI or associated sequelae, either morbidity and mortality
- 6. Specific information on demographic (race, gender, educational status, socioeconomic status or insurance status) was lacking

Conclusions and Next Steps

Despite limitations, this project suggests that the immunization needs of this asplenic cohort may not have been met • Limitations reflect opportunities for improvement in future quality assurance efforts assessing immunization trends among highrisk adults

• A targeted full chart review of a random sample of the subjects included in this project is suggested

• The goal should be to capture full immunization histories and data points that were not accessed during this project

• A literature review described strategies that have been shown to improve immunization coverage among asplenic patients:

- Establish a plan to screen asplenic patients, evaluating their need for immunizations and/or other services
- Use of Immunization Standing Orders for asplenic patients
- Assign a nurse practitioner to assess and monitor asplenic patients, providing vaccines and follow-up patient education

Acknowledgments

• Linda Ohri, Pharm.D., M.P.H, Immunization Task Force – Metro Omaha

• Rudolf Kotula, MD, FACP, FIDSA - Methodist Physicians Clinic • Laurie O'Byrne, Susan Arens, and Mary Thomas – Methodist Physicians Clinic

• Bud Shaw, M.D. – UNMC COM

• Armando De Alba Rosales, M.D., M.P.H. – UNMC COPH *References available upon request

> Vedias of Medical Center